Last June, the National Academies' Institute of Medicine hosted a two-day workshop in Washington, DC, aimed at promoting clinical research in dogs that can be translated to finding new cures for people. Now the IOM is sharing insights that came from the more than 20 veterinarians and scientists who attended the event.
Biopharmas may be able to command hundreds of dollars a month for prescription medications, but it can be tough to get payers to cough up even a few bucks for an app that may offer comparable levels of benefit. So, one startup, Pear Therapeutics, has adopted the language of biopharma and it is looking to work tightly in tandem with drug companies with medication adherence apps.
The Michael J. Fox Foundation awarded a grant to Evotec to support the company's work in Parkinson's disease, bankrolling a project meant to clear the way for new therapies.
Cambridge, MA's Spero Therapeutics has raised $30 million in Series B financing to develop its so-called Potentiator Platform to improve existing antibiotics by enabling them to pass through the cell membrane of Gram-negative bacteria.
Cats with a debilitating tooth ailment called feline chronic gingivostomatitis sometimes experience pain even after getting their teeth removed or taking multiple doses of antibiotics or steroids. But a new treatment that draws on the cats' own stem cells could prove game-changing in helping animals that are suffering from the disease. The findings could also apply to humans with oral diseases.
LAM Therapeutics, a biotech co-founded by Yale University entrepreneur Jonathan Rothberg, raised $40 million to fund its work on an early-stage pipeline of treatments for rare diseases and cancer.
Researchers at UT Southwestern Medical Center have discovered a new drug that could help in vaccine development. It activates the innate immune system in a novel way.
Whatever Takeda learned about Cambridge, MA-based Mersana Therapeutics over the course of its two-year collaboration, the experience left them eager for much, much more. The biotech announced today that the Japanese pharma company snagged ex-U.S. commercial rights to its lead preclinical antibody drug conjugate while expanding the realm of their partnership to include a range of new targets.
As the global alarm continues to sound about the Zika virus, Sanofi said on Tuesday that it's getting involved. In doing so, it became the first major pharmaceutical company to get involved in the Zika vaccine race, launching a program to develop a jab just after receiving the first regulatory approvals for its dengue shot.
Onyx Scientific is set to increase the size of its U.K.-based site by more than 30% as it enjoys the spoils of a lucrative 2015.